Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$9.82 - $12.75 $16,546 - $21,483
-1,685 Reduced 10.1%
15,000 $157,000
Q2 2022

Aug 15, 2022

SELL
$6.23 - $11.12 $2,161 - $3,858
-347 Reduced 2.04%
16,685 $173,000
Q1 2022

May 16, 2022

SELL
$7.89 - $12.48 $284,718 - $450,353
-36,086 Reduced 67.94%
17,032 $161,000
Q4 2021

Feb 10, 2022

BUY
$9.82 - $12.44 $45,378 - $57,485
4,621 Added 9.53%
53,118 $613,000
Q3 2021

Nov 15, 2021

BUY
$8.74 - $11.84 $101,724 - $137,805
11,639 Added 31.58%
48,497 $463,000
Q2 2021

Aug 10, 2021

BUY
$8.71 - $10.72 $321,033 - $395,117
36,858 New
36,858 $355,000
Q2 2019

Aug 12, 2019

SELL
$10.96 - $14.4 $3,792 - $4,982
-346 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$8.38 - $13.44 $2,899 - $4,650
346 New
346 $331,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.7B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Cresset Asset Management, LLC Portfolio

Follow Cresset Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cresset Asset Management, LLC with notifications on news.